NCT00850616View on ClinicalTrials.gov

Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)

PHASE1CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

March 31, 2011

Conditions
HIVHIV Infections
Interventions
BIOLOGICAL

V526

0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.

BIOLOGICAL

Comparator: Placebo to V526

0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00850616 - Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED) | Biotech Hunter | Biotech Hunter